NeoGenomics (NEO) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Tycho Peterson from the Life Science Tools Group. It's my pleasure to introduce our next company this afternoon, NeoGenomics. Tony, I'm going to maybe open it up with you. You've had a little bit of time in the CEO role here. Just talk about early learnings, how you're kind of thinking about stepping in, any big changes that need to happen? Speaker1 No. I think it's been a really good introductory period for me. I had the op ...

NeoGenomics (NEO) FY Conference June 03, 2025 01:00 PM ET Speaker0 All right, hi everyone. Good afternoon. Thanks for joining us here. First day of the William Blair Growth Stock Conference. If you don't know me, I'm Andrew Brackman. I'm the diagnostics analyst here at William Blair. On my team, Maggie Bowie and Kate Jansen here in the second row. You see us around the conference, feel free to say hi. We're happy to chat anything and everything diagnostics. With us today we have NeoGenomics. We have the who ...

业绩总结 - 2025年第一季度收入为1.68亿美元，同比增长8%[36] - 调整后的毛利润为7900万美元，同比增长11%[31] - 调整后的EBITDA为700万美元，同比增长102%[31] - 2025年第一季度净亏损为2592.3万美元，较上年减少[47] - 2025年第一季度总收入为168,035千美元，较2024年同期的156,240千美元增长7.5%[51] - 2025年第一季度毛利为73,246千美元，较2024年同期的65,469千美元增长11.9%[51] - 2025年第一季度调整后EBITDA为7,070千美元，较2024年同期的3,492千美元显著增长[53] - 2025年第一季度净损失为25,923千美元，较2024年同期的27,061千美元有所减少[53] 用户数据 - 临床NGS收入增长18%[17] - 临床测试量同比增长8%，达到32.6万单位[31] 未来展望 - 预计2025财年收入指导范围为7.47亿至7.59亿美元，同比增长13%至15%[38] - 2025年预计净损失范围为77,000千美元至85,000千美元[57] 新产品和新技术研发 - Pathline收购预计将增加1200万至1400万美元的收入[38] 现金流和财务状况 - 现金及现金等价物为3.46亿美元，较上年增长4.3%[36] - 2025年第一季度现金及现金等价物期末余额为346,194千美元，较2024年同期的331,914千美元有所增加[49] - 2025年第一季度净现金用于经营活动为25,327千美元，较2024年同期的25,915千美元有所改善[49] - 2025年第一季度投资活动提供的净现金为3,560千美元，较2024年同期的14,525千美元下降[49] 其他信息 - 调整后的毛利率提高至47%，较上年增加146个基点[32] - 2025年第一季度调整后毛利率为46.8%，较2024年同期的45.3%有所提升[51] - 2025年第一季度股权激励费用为10,754千美元，较2024年同期的7,774千美元增加[53]